Impact and cost-effectiveness of nonavalent human papillomavirus vaccination in Switzerland: insights from a dynamic transmission model

Maurane Riesen; Johannes A. Bogaards; Nicola Low; Christian L. Althaus

doi:10.1101/19012674

Article Information

doi

https://doi.org/10.1101/19012674

History

December 11, 2019.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

Maurane Riesena,b,
Johannes A. Bogaardsc,d,
Nicola Lowa and
Christian L. Althaus*,a

^aInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
^bGraduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland
^cDepartment of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
^dNational Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control, Bilthoven, The Netherlands